BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameBCMA Targeted CAR-T Cell Therapy (Yake Biotechnology)
Drug Alias NameAnti BCMA CART cell therapy - Shanghai YaKe BiotechnologyAnti BCMA CART cell therapy (Shanghai YaKe Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A